wAIHA: Treatment Options – Current and In Development
wAIHA: Treatment Options – Current and In Development is organized by American Academy of CME, Inc..
Start date: June 01, 2023
End date: May 31, 2024
Activity Description
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due to an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis. Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future. This 30-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current treatment options, and treatments in development, for patients with wAIHA.
Learning Objectives:
After participating in the activity, learners should be better able to:
• Explain current treatment recommendations for patients with wAIHA and the evidence which supports them
• Describe potential therapies in development for treating patients with wAIHA
Additional details will be posted as soon as information is available.